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Background: Cardiac magnetic resonance (CMR) T1 mapping has been used to characterize myocardial diffuse
fibrosis. The aim of this study is to determine the reproducibility and sample size of CMR fibrosis measurements
that would be applicable in clinical trials.
Methods: A modified Look-Locker with inversion recovery (MOLLI) sequence was used to determine myocardial T1
values pre-, and 12 and 25min post-administration of a gadolinium-based contrast agent at 3 Tesla. For 24 healthy
subjects (8 men; 29 ± 6 years), two separate scans were obtained a) with a bolus of 0.15mmol/kg of gadopentate
dimeglumine and b) 0.1mmol/kg of gadobenate dimeglumine, respectively, with averaged of 51 ± 34 days between
two scans. Separately, 25 heart failure subjects (12 men; 63 ± 14 years), were evaluated after a bolus of 0.15mmol/kg
of gadopentate dimeglumine. Myocardial partition coefficient (λ) was calculated according to (ΔR1myocardium/
ΔR1blood), and ECV was derived from λ by adjusting (1-hematocrit).
Results: Mean ECV and λ were both significantly higher in HF subjects than healthy (ECV: 0.287 ± 0.034 vs.
0.267 ± 0.028, p=0.002; λ: 0.481 ± 0.052 vs. 442 ± 0.037, p < 0.001, respectively). The inter-study ECV and λ
variation were about 2.8 times greater than the intra-study ECV and λ variation in healthy subjects (ECV:0.017 vs.
0.006, λ:0.025 vs. 0.009, respectively). The estimated sample size to detect ECV change of 0.038 or λ change of
0.063 (corresponding to ~3% increase of histological myocardial fibrosis) with a power of 80% and an alpha
error of 0.05 for heart failure subjects using a two group design was 27 in each group, respectively.
Conclusion: ECV and λ quantification have a low variability across scans, and could be a viable tool for
evaluating clinical trial outcome.Background
Diffuse myocardial fibrosis (DMF) is a common histo-
logical feature of the failing heart and is present in many
conditions, ranging from advanced aging to hypertension
or hypertrophic cardiomyopathy [1-3]. DMF is thought
to be primarily responsible for increased myocardial
stiffness and diastolic dysfunction: an increasingly com-
mon condition in the elderly [4,5]. Endomyocardial
biopsy (EMB) is the standard of reference for quantifying* Correspondence: bluemked@cc.nih.gov
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reproduction in any medium, provided the orDMF, but is an invasive procedure and prone to sam-
pling error [6,7].
Myocardial composition may be probed noninvasively
by measuring the T1 time of the myocardium, termed T1
mapping. DMF results in increased collagen content with
expansion of the extracellular space to a greater extent
than that of normal myocardium [8,9], resulting in accu-
mulation of gadolinium-based contrast agents (GBCA).
This, in turn, lowers the T1 time of the myocardium.
Altered myocardial T1 times have been demonstrated in a
range of nonischemic cardiomyopathies [10], including
chronic aortic regurgitation [11], heart failure [7], aortic
stenosis [12], and adult congenital heart disease [13].
Unfortunately, absolute quantification of T1 time is
influenced by many factors, including the relaxivity ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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function (glomerular filtration rates, GFR) [14]. As an al-
ternative, other indices of DMF have been considered,
such as extracellular volume fraction (ECV) and parti-
tion coefficient (λ) [15-18]. Of note, there is considerably
less change in ECV over time at steady state compared
to relatively large changes in T1 values as a function of
time after GBCA injection [19,20]. In addition, ECV is
relatively robust as a function of field strength [21].
Thus, ECV and partition coefficient are likely to be more
favorable measures to determine change in DMF as a
result of treatment or disease.
Therapeutic agents targeted at reducing DMF have been
actively investigated in animal models [22-24]. To date, no
human prospective studies with the goal of reducing DMF
have been reported. In order to provide utility as a bio-
marker for longitudinal studies, one must estimate the test,
re-test (inter-study) reproducibility of ECV and partition
coefficient. Inter-study reproducibility in turn is affected
by factors such as measurement error (e.g. due to patient
motion or reader variability), variation in MRI scanner
performance or pulse sequences and contrast agents.
Knowledge of inter-study reproducibility can be used to
estimate the sample size needed to demonstrate a statisti-
cally significant change in ECV or partition coefficient.
The purpose of this study was to estimate the variability
of quantitative T1 measurements and, in particular, of the
derived values of ECV and partition coefficient. We then
provide sample size estimates to determine the potential
of cardiac magnetic resonance (CMR) T1 data to be used
as a noninvasive biomarker aimed at identifying reduction
of DMF in response to a therapeutic intervention.
Methods
Study population
This study was approved by our institutional review
board. All study participants provided written informed
consent. Twenty-four healthy volunteers (8 men; 29 ± 6
years) without a history of cardiovascular or systemic
disease were enrolled. The ECG obtained prior to the
CMR exam did not show any abnormality and the phy-
sical exam performed by a physician did not reveal any
pathologic finding. Normal left ventricular (LV) and
right ventricular (RV) volumes and systolic functions
were confirmed by CMR. The healthy subjects’ data has
been previous published by our group [25]. In addition,
twenty-five heart failure (HF) subjects (12 men; mean
age ± SD, 63 ± 14 years) with NYHA classification II or
greater were enrolled.
CMR protocol
All CMR exams were performed using a 3-Tesla scanner
(Verio, Siemens Medical Systems, Erlangen, Germany)
with a 32-channel cardiovascular array coil. T1quantification was performed with a modified Look-
Locker with inversion recovery (MOLLI) sequence [26]
acquired during end-expiratory apnea in a mid-ventricular
short axis view before and 12, and 25 minutes after
GBCA. The MOLLI protocol has two inversion blocks;
three images are acquired after the first inversion
pulse, followed by a pause of three heart beats, then
five images are acquired after a second inversion pulse
[20]. Other CMR parameters were: non-segmented,
steady state free precession read out in mid-diastole;
FOV 290 to 360 mm; readout resolution 192; phase
resolution 75% to 85%; slice thickness 8 mm; TR/TE
1.9/1.0ms, minimum inversion time 110ms, inversion
time increment 80ms, flip angle 35°; GRAPPA parallel
imaging factor 2, no partial Fourier in the phase en-
code dimension.
GBCA was injected intravenously at 2 ml/sec using a
power injector and followed by a 20ml saline bolus
administered at the same flow rate. Both healthy
and HF subjects underwent CMR examination with
0.15mmol/kg of gadopentate dimeglumine. Healthy
volunteers also underwent another CMR examination
with the same CMR protocol with 0.1mmol/kg of gado-
benate dimeglumine. The mean delay between the two
studies was 51 ± 34 days.
Left ventricular volume and function were evaluated
with steady state free precession cine imaging in short
axis stack and in three long axis views. Late gadolinium
enhancement (LGE) was acquired in the same position
as cine images using a phase sensitive inversion reco-
very gradient echo sequence [27] after 15min of GBCA
injection. Blood samples were taken 1 to 4 hours prior
to the CMR to determine the HCT and creatinine.Image analysis
T1 maps were generated by three points pixel-wise
curve fitting [28] and stored in Digital Imaging and
Communications in Medicine (DICOM) Format. To ex-
tract myocardial T1 value, endocardial and epicardial
contours were manually traced using QMass MR 7.2
(Medis, Leiden, Netherlands), and the myocardial cir-
cumference was divided into segments according to the
American Heart Association 17-segment model [29].
Care was taken to exclude epicardial structures and
blood from the contours. T1 value of the blood pool
was measured by manually drawing a region of interest
in the left ventricular cavity excluding papillary muscles.
The image quality for all segments was visually rated
using a scale in which a score of 3 indicated that image
quality was good, with no artifacts; a score of 2, that
image quality was satisfactory, with minor artifacts; and
a score of 1, that an image was non-evaluable with
major artifact, as described by Messroghli [30]. T1





Age 28.6 ± 5.9 62.7 ± 14.3
Male 8 (33.3) 12 (48.0)
Hematocrit (%) 39.7 ± 3.8 40.5 ± 3.1
Serum creatinine
(mg/dL)
0.75 ± 0.15 0.91 ± 0.28
eGFR (ml/min) 115.5 ± 21.5 82.3 ± 18.5
Medical history
Diabetes Mellitus(%) 0 (0) 2 (8.0)
Smoking 3 (12.5) 1 (4.0)
Hypertension 0 (0) 14 (56.0)
Hyperlipidemia 0 (0) 8 (40.0)
LV function by CMR
EDV (ml) 147.6 ± 31.8 214.8 ± 116.5
ESV (ml) 56.5 ± 14.9 133.9 ± 104.5
EF (%) 61.9 ± 4.0 42.1 ± 18.7
Mass (g) 111.0 ± 36.6 203.0 ± 110.6
Stroke volume (ml) 91.1 ± 19.4 81.0 ± 43.7
Note: Mean and standard deviation or number and percentage as appropriate.
LV, left ventricular; EDV, end-diastolic volume; ESV, end-systolic volume; EF,
ejection fraction.
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were excluded from analysis. ECV and λ values were
calculated according to the following formulae [15]:
ΔR1myo ¼ 1=T1myopost  1=T1myopre ð1Þ
ΔR1blood ¼ 1=T1bloodpost  1=T1bloodpre ð2Þ
λ¼ΔR1myo=ΔR1blood ð3Þ
ECV ¼ λ 100HCTð Þ ð4Þ
Where ECV, λ, and HCT are given as percentages.
Statistical analysis
Statistical analyses were performed using SAS 9.1 (Cary,
North Carolina, USA) and MedCalc 12.2 (MedCalc Soft-
ware, Mariakerke, Belgium). Sample size estimation was
performed using PASS 2008 (Kaysville, Utah, USA). For
comparison of the means between groups, one-way analysis
of variance with post-hoc comparison was performed. Data
are presented as mean ± standard deviation. Statistical sig-
nificance was defined as P < 0.05.
The intra-study and inter-study reproducibility were
assessed by calculating the difference and standard
deviation between results. The coefficient of variability
was calculated as the standard deviation of the difference
divided by the mean of the parameter under consider-
ation. Intra-study reproducibility compares the differ-
ence of ECV and partition coefficient at the 12-minute
and 25-minute time points of the same study session:
this is the best case scenario for testing ECV and parti-
tion coefficient reproducibility. Inter-study reproducibi-
lity, which compares ECV and partition coefficient
results of two different study sessions, is the standard
test-retest reliability. The inter-study reproducibility –
the standard deviation of the mean difference – is the
key factor for determining the ability of a technique to
perform longitudinal examinations to detect a change.
High reproducibility (low inter-study standard deviation)
leads to greater reliability of observed changes in a par-
ameter and a smaller sample size in clinical trials.
The sample size required by ECV or λ to show a clin-
ical change with a power of 80% and an α error of 0.05
were calculated using the following formula:
n ¼ f a; Pð Þσ2 2=δ2 ð5Þ
Where n is the sample size needed, α is the significant
level, P is the study power required, and f is the value of
the factor for different values of α and P, with σ as the
inter-study standard deviation and δ as the desired dif-
ference to be detected [31,32].
Results
Study subject characteristics are given in Table 1. CMR
was well tolerated by all subjects in the study. Both ECVand λ were significantly higher in the heart failure group
compared to the healthy group (ECV: 0.287 ± 0.034 vs.
0.267 ± 0.028, p = 0.002; λ: 0.481 ± 0.052 vs.442 ± 0.037,
p < 0.001). For the healthy group, there was no statis-
tical difference between 12 minute and 25 minute ECV
and λ (ECV: 0.264 ± 0.028 vs. 0.271 ± 0.028, p = NS;
λ:0.436 ± 0.038 vs. 0.447 ± 0.037, p = NS). In addition,
there was no significant difference for these parameters
between gadopentetate dimeglumine and gadobenate
dimeglumine (ECV: 0.271 ± 0.027 vs. 0.264 ± 0.029,
p = NS; λ: 0.449 ± 0.039 vs. 0.435 ± 0.035, p=NS). Simi-
larly, there was no statistical difference between 12 mi-
nute and 25 minute ECV and λ (ECV, 0.282 ± 0.033 vs.
0.289 ± 0.034, p = NS; λ: 0.475 ± 0.053 vs. 0.487 ±
0.051, p = NS) in the heart failure group. These results
confirm the stability of ECV over moderate time inter-
vals, and suggest a similar biodistribution of the two
contrast agents. Of note, the image quality of T1 maps
was significantly better in healthy group (2.8 ± 0.2 for
healthy, 2.6 ± 0.4 for heart failure, p < 0.001).
Repeat measures of ECV and λ, intra-study assessment
The intra-study data of ECV and λ for both normal and HF
groups are shown in Table 2. As expected, the correlation
between the 12 minute and 25 minute of ECV and λ in the
same study session was better in healthy subjects (0.98,
0.97) compared with that of the heart failure patients (0.88,
0.86). ECV has smaller Bland-Altman limits of agreement
and intra-study standard deviation compared with partition
Table 2 Intra-study reproducibility data in healthy and heart failure groups
Healthy subjects Heart failure subjects
λ ECV λ ECV
Mean ± SD 0.442 ± 0.037 0.267 ± 0.028 0.481 ± 0.052 0.286 ± 0.034
Min: Max 0.367 : 0.530 0.202 : 0.325 0.368 : 0.634 0.240 : 0.398
Mean Diff ± SD 0.012 ± 0.009 0.007 ± 0.006 0.012 ± 0.028 0.007 ± 0.017
Corr Coef 0.97 0.98 0.86 0.88
CV 0.020 0.022 0.058 0.059
BA limit -0.03 : 0.006 -0.018 : 0.004 -0.068 : 0.043 -0.041 : 0.026
λ: partition coefficient; ECV: extracellular volume fraction; Mean Diff, mean difference; Corr Coef, correlation coefficient; CV, coefficient of variability; BA limit, Bland-
Altman limits of agreement.
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ECV and λ was larger in the heart failure group compared
to that of the healthy group.Table 4 Estimated sample size in heart failure group toInter-study difference and sample size estimation
The inter-study data of ECV and λ of the healthy group are
shown in Table 3. Compared with the same intra-study data
parameters, the correlation coefficients were lower for data
acquired at a different study session. As expected, the CV
and Bland-Altman limits of agreement of inter-study were
also greater compared with that of the intra-study. Pre-
contrast myocardial T1 exhibits high agreement between
two study sessions.
In healthy subjects, the inter-study SD of ECV and λ were
about 2.8-fold greater than the intra-study (ECV: 0.017 vs.
0.006; λ 0.025 vs. 0.009). In heart failure subjects, the intra-
study of ECV and λ were 0.017 and 0.028, respectively. The
sample size needed for the heart failure group was esti-
mated for three different cases:
Case 1 Inter-study SD of ECV and λ estimated at 2.8
times greater than the intra-study SD (SD1 and
N1 in Table 4),
ECV SD int erstudy ¼ ECV SD int rastudy  2:8 ¼ 0:017 2:8
¼ 0:048
λ SD int erstudy ¼ λ SD int rastudy  2:8 ¼ 0:028 2:8





Mean ± SD 1159.0 ± 39.2 0.442 ± 0.037 0.267 ± 0.028
Mean Diff ± SD -9.4 ± 29.2 -0.016 ± 0.025 -0.006 ± 0.017
Corr Coef 0.75 0.78 0.82
CV 0.025 0.057 0.064
BA limit -47.8 : 66.6 -0.033 : 0.066 -0.027 : 0.040
λ : partition coefficient; ECV: extracellular volume fraction; Mean Diff, mean
difference; Corr Coef, correlation coefficient; CV, coefficient of variability; BA
limit, Bland-Altman limits of agreement.Case 2 50% more variation than Case 1: Inter-study SD of
ECV and λ estimated at 4.2 times greater than the
intra-study SD (SD2 and N2 in Table 4),
ECV SD int erstudy ¼ ECV SD int rastudy  4:2 ¼ 0:017 4:2
¼ 0:072
λ SD int erstudy ¼ λ SD int rastudy  4:2 ¼ 0:0284:2
¼ 0:117
Case 3 100% more variation than Case 1: Inter-study
SD of ECV and λ estimated at 5.6 times greater
than the intra-study SD (SD3 and N3 in
Table 4),
ECV SD int erstudy ¼ ECV SD int rastudy  5:6 ¼ 0:017 5:6
¼ 0:096
λ SD int erstudy ¼ λ SD int rastudy  5:6 ¼ 0:028 5:6
¼ 0:156
Sample size estimation
In patients without LGE, the median percent histological
fibrosis was 6.5% with inter-quartile range of 3.0 – 9.0%
at endomyocardial biopsy [34]. Therefore, a 3% increase
of histological fibrosis represents 25% more myocardial
fibrosis over baseline would be clinically meaningful.
The correlation coefficient between ECV quantificationdetect the change of ECV and λ with a power of 80%
Clinical change Caset 1 Case 2 Case 3
SDD1 N1 SDD2 N2 SDD3 N3
λ (0.063) 0.078 26 0.117 56 0.156 98
ECV (0.038) 0.048 27 0.072 58 0.096 102
Sample size need to detect a clinical meaning change of ECV and λ with 80%
of power and an alpha error of 0.05. Sample size is derived from the inter-
study SDD as described by Altman [33] and Marchin [32]. Note that for studies
comparing active vs. placebo, these sample size numbers need to be doubled.
Case 1: the inter-study SDD1 in HF group was estimated 2.8 fold greater than
the intra-study SDD; Case 2, the inter-study SDD2 was estimated 1.5 times
more than SDD1; Case3, the inter-study SDD3 was estimated 2 times more
than SDD1.
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model [35]; and 0.89 in aortic stenosis and hypertrophic
cardiomyopathy patients [12]. Take the average ECV cor-
relation coefficient and the proposed 3% increase of
histological fibrosis translates into a clinically meaning-
fully ECV change of 0.038 or lambda change of 0.063,
assuming a hematocrit of 0.4.
For Case 1, 27 patients would be needed to detect a
0.038 change in ECV or 0.063 change in λ with 80% of
power. For a “worst case” scenario with more variability as
in Case 3 (e.g., a multi-center trial), 100 patients would be
needed to detect a 0.038 change in ECV or 0.063 change
in λ with 80% of power. For studies comparing active
treatment vs. placebo, these sample size numbers need to
be doubled. Figure 1 and Figure 2 show the sample sizes
required for detection of a certain ECV or λ difference
with a power of 80% and an alpha error of 0.05 under dif-
ferent inter-study standard deviations.
Discussion
DMF is a common endpoint associated with a wide range
of cardiomyopathies. Preclinical studies have shown a re-
duction in DMF in response to angiotensin converting en-
zyme inhibitors [24,36,37] and N-acetylcysteine [22,23].
For a similar human clinical trial, a paired study design
offers more power to assess treatment response than an
unpaired design. In this analysis, we provide estimates that
are useful for such a paired study design, allowing the fol-
lowing conclusions: a) sample size needed to detect aFigure 1 Sample size required in each group to detect a certain ECV
error of 0.05. The X axis values corresponding to the ECV difference need
corresponding to case 1, 2 and 3 of Table 4. The smaller ECV difference an
line corresponding to the sample size needed to detect a 0.038 ECV differemeaningful clinical change are similar for ECV and parti-
tion coefficient; b) sample size estimates become highly
sensitive to the inter-study reproducibility for a target
change in ECV of less than 0.04-0.05; and c) sample sizes
of 50-100 subjects in each study arm are likely to be ne-
cessary to detect changes of 0.03-0.05 in ECV for inter-
study standard differences on the order of 0.05. Note that
these sample size estimates would be equally applicable to
a scenario that sought to halt progression of DMF, under
the assumption that DMF would otherwise show a defined
rate of increase over time.
CMR using LGE technique has been the standard of
reference for detecting focal myocardial replacement fi-
brosis or scarring fibrosis in conditions such as myocardial
infarction and hypertrophic cardiomyopathy [38,39]. LGE
relies on the differences in signal intensity between scarred
and adjacent normal myocardium to generate image con-
trast [27,40]. In an animal model of hypertension-induced
DMF, LGE failed to detect any hyper-enhancement while
histology analysis revealed an average of 9.9% collagen vo-
lume fraction [35]. Similarly, in cardiomyopathy patients,
endomyocardial biopsy revealed the presence up to 20%
diffuse myocardial fibrosis in patients without evidence of
LGE [10]. Therefore, the detection of subtle DMF poses a
significant challenge to LGE.
Extracellular volume fraction by CMR is a promising
tool for visualization and quantification of local and dif-
fuse myocardial abnormalities [15,16,41]. An animal study
has demonstrated that elevated ECV was associated withdifference with a two group design of 80% power and an alpha
to be detected like the first column in Table 4. The three curves
d higher inter-study SD, the larger the sample size needed. The dashed
nce for the three cases as showed in Table 4.
Figure 2 Sample size required in each group to detect a certain partition coefficient difference with a two group design of 80% power
and an alpha error of 0.05. The X axis values corresponding to the partition coefficient difference need to be detected like the first column in
Table 4. The three curves corresponding to case 1, 2 and 3 of Table 4. The smaller partition coefficient difference and higher inter-study SD, the
larger the sample size needed. The dashed line corresponding to the sample size needed to detect a 0.063 partition coefficient difference for the
three cases as showed in Table 4.
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have been published using ECV as a surrogate biomarker
for DMF [12,13,17,18]. The reproducibility of a technique
determines the sample size required to demonstrate a
clinical change [42], which is a major cost in clinical trials.
Messroghli reported the reproducibility data of myocardial
T1 in a group of healthy volunteers [30], but there is a
lack of data with regard to the reproducibility of ECV and
partition coefficient.
In this study, there is good intra-study agreement
between 12 minute and 25 minute ECV and partition co-
efficient in healthy volunteers, and this compares favorably
with previous reports that ECV and partition coefficient
are relatively stable after reaching the dynamic equilibrium
between myocardium and blood pool [19,43]. The intra-
study variability of ECV and λ is higher in heart failure
subjects. The primary reason for this was reduced image
quality for heart failure subjects. Such patients have
reduced capacity for breath-holding, resulting in motion
artifacts. The MOLLI protocol used in this study requires
a 11-heart-beat breath-hold, 5 heart beats shorter than the
classic 17 heart beats MOLLI [44]. An even faster MOLLI
protocol, like shMOLLI with 9 heart beats might be help-
ful in this regard [45]. Xue et al. [46] demonstrated a mo-
tion correction algorithm using image registration with
synthetic image estimation to suppress the motion-
induced artifacts in T1 maps. Robust motion correction
was achieved by registering synthetic images to thecorresponding MOLLI frames, and this method has been
incorporated into the inline T1 mapping calculation of
some scanners. In the future, a free-breathing T1 acquisi-
tion with motion correction would be ideal for the heart
failure patients.
High reproducibility (low inter-study standard devia-
tion) leads to greater reliability of observed changes in a
parameter. This also results in cost-efficiency, as smaller
sample size is required in clinical trials. Our sample size
calculation demonstrates that a reasonable sample size is
needed to detect a clinically meaningful change in ECV
and partition coefficient.
Previously, CMR has successfully shown group diffe-
rences in parameters such as T1 time or ECV between
normal versus diseased study subjects [7,15]. In this
study, we also demonstrated statistically significant group
differences in ECV using a relatively small sample size
(24 normal subjects versus 25 HF subjects). However,
the mean ECV value of the HF subjects (0.286) was
within the observed range of values in normal subjects,
previously reported to be 0.24-0.27 [13,15,19,20]. Using
a cut-value for normal ECV of 0.267, the sensitivity to
detect abnormal ECV in HF subjects was only 38%.
Thus, ECV is less likely to be useful as single cut-off
value to identify abnormal versus normal subjects. How-
ever, change in ECV within an individual may be a more
promising approach to assess, for example, a therapeutic
response.
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estimated inter-study standardized differences for the
heart failure patients using the healthy subjects as a
reference group. Repeat gadolinium-enhanced MRI
scans over a short interval was not performed due
to below normal renal function in the HF group. Our
estimates nevertheless appear to be of the correct mag-
nitude. We experimentally detected a statistical signifi-
cance in ECV with a total sample size of 49 in the study
(24 in healthy group and 25 in heart failure group), simi-
lar to the 54 total sample size we estimated (27 subjects
in each arm with 80% of power and an alpha error of
0.05). In addition, this is a single-center study. All scans
were preformed on a single scanner with good adhe-
rence to the study protocol. For multi-center studies in-
volving multiple scanners, a higher degree of variation is
expected because of the difference of sequences, ima-
gers, coil systems, and field strengths [47]. The inter-
study reproducibility is related to sample size by a
square function, therefore a much larger sample size is
needed to compensate the increased variation in a
multi-center study to detect ECV or partition coefficient
change (Figure 1 and Figure 2).Conclusion
In conclusion, ECV and partition coefficient have a rela-
tively low variability for repeat scans, and could be a
viable tool for evaluating clinical trial outcome. Sample
size estimation showed that a study with 27 participants
in each group could detect a 0.038 change in ECV or
0.063 change in partition coefficient with 80% of power,
which corresponding to about 3% increase in histological
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